Adams Kusi Appiah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adams Kusi Appiah has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Fabrice André
Gustave Roussy, Villejuif, France
21 shared publications - Hannelore Denys
Department of Medical Oncology, Ghent University Hospital, 9000 Ghent, Belgium
21 shared publications - Jiangang Liu
Eli Lilly and Company, Indianapolis, Indiana
21 shared publications - Jorge Nadal
Alexander Fleming Institute, Buenos Aires, Argentina
21 shared publications - Lacey M. Litchfield
Eli Lilly and Company, Indianapolis, Indiana
21 shared publications - Manuel Ruiz-Borrego
Medical Oncology Department, Virgen del Rocio University Hospital, Sevilla, Spain
21 shared publications
Latest Publications
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Summary of patient disposition and list of study inclusion and exclusion criteria.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Summary of patient disposition and list of study inclusion and exclusion criteria.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Post-discontinuation therapies.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Post-discontinuation therapies.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
List of study key endpoints and definitions.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
List of study key endpoints and definitions.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Best overall response by RECIST v1.1 criteria without concurrent bone progression.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Best overall response by RECIST v1.1 criteria without concurrent bone progression.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
List for representativeness of study participants.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
List for representativeness of study participants.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Summary of patient disposition and list of study inclusion and exclusion criteria.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Summary of patient disposition and list of study inclusion and exclusion criteria.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Kaplan-Meier curve of time to symptomatic progression.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Kaplan-Meier curve of time to symptomatic progression.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Best overall response by RECIST v1.1 criteria without concurrent bone progression.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1
Best overall response by RECIST v1.1 criteria without concurrent bone progression.